Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 10 Jul 2022
Prices and clinical benefit of national price negotiated anti-cancer medicines in China
8 July 2022 - High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. ...
Posted by Michael Wonder on 10 Jul 2022
Human genetics evidence supports two-thirds of the 2021 FDA approved drugs
8 July 2022 - In 2021, 50 drugs were approved by the FDA’s Center for Drug Evaluation and Research, continuing a ...
Posted by Michael Wonder on 10 Jul 2022
Millions of Australians to gain access to COVID treatments
10 July 2022 - Eligibility for potentially lifesaving COVID-19 antiviral treatments will be widened from tomorrow, Monday 11 July. ...
Posted by Michael Wonder on 10 Jul 2022
COVID-19 oral treatment eligibility expanded from 11 July 2022
10 July 2022 - From 11 July 2022, more Australians at higher risk of developing severe COVID-19 will be able to ...
Posted by Michael Wonder on 10 Jul 2022
Celltrion Pharm's liver disease drug may lose insurance benefits
8 July 2022 - Celltrion's prescription liver disease treatment Godex might lose reimbursement because the HIRA recently decided to withdraw ...
Posted by Michael Wonder on 10 Jul 2022
PBAC recommendation for amendments to COVID-19 oral treatment restrictions
10 July 2022 - The PBAC recommended changes to the PBS eligibility criteria for both molnupiravir (Lagevrio) and nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 10 Jul 2022
Monkeypox: a preventive vaccination offered to those most at risk of exposure
8 July 2022 - Faced with the spread of the Monkeypox virus, the kinetics of the epidemic and the difficulties of ...
Posted by Michael Wonder on 10 Jul 2022
Pfizer and BioNTech submit a variation to EMA for the vaccination of children 6 months to less than 5 years with Comirnaty
8 July 2022 - y 8, 2022 — Pfizer and BioNTech today announced that the companies have submitted a variation to ...
Posted by Michael Wonder on 09 Jul 2022
FDA approves Krystexxa (pegloticase) injection co-administered with methotrexate, expanding the labelling to help more people with uncontrolled gout achieve a complete response to therapy
8 July 2022 - Approval based on MIRROR randomised controlled trial, which showed significant improvement and sustained patient response to Krystexxa ...
Posted by Michael Wonder on 09 Jul 2022
Pfizer and BioNTech announce U.S. FDA approval of their COVID-19 vaccine Comirnaty for adolescents 12 through 15 years of age
8 July 2022 - Approval of the two dose primary series is based on the totality of data through six months ...
Posted by Michael Wonder on 08 Jul 2022
NICE recommends Opdivo as post-surgery treatment
8 July 2021 - The therapy will be used for specific muscle invasive urothelial cancer patients ...
Posted by Michael Wonder on 08 Jul 2022
World’s first chemo drone delivery announced on NHS birthday
5 July 2022 - NHS cancer patients will be the first in the world to benefit from chemotherapy delivered by ...
Posted by Michael Wonder on 08 Jul 2022
Doctors, pharmacists call for better support to prescribe anti-virals
8 July 2022 - Pandemic measures including home delivery of medicines and subsidised Telehealth appointments should be reinstated to allow ...
Posted by Michael Wonder on 07 Jul 2022
US FDA awards rare paediatric disease designation to paxalisib for AT/RT, a rare form of childhood brain cancer
6 July 2022 - Kazia Therapeutics is pleased to announce that the U.S. FDA has awarded rare paediatric disease designation ...
Posted by Michael Wonder on 07 Jul 2022
MSAC updates agenda for July 2022 meeting
7 July 2022 - One application has been added. ...